2024 Q2 Form 10-Q Financial Statement
#000149315224019221 Filed on May 14, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| Revenue | ||
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $324.9K | $359.9K |
| YoY Change | 2.37% | 7.13% |
| % of Gross Profit | ||
| Research & Development | $240.4K | $232.6K |
| YoY Change | 9.71% | 57.32% |
| % of Gross Profit | ||
| Depreciation & Amortization | $1.364K | $1.523K |
| YoY Change | -20.47% | -11.2% |
| % of Gross Profit | ||
| Operating Expenses | $602.8K | $630.0K |
| YoY Change | 5.02% | 20.86% |
| Operating Profit | -$602.8K | -$630.0K |
| YoY Change | 5.02% | 20.86% |
| Interest Expense | -$128.1K | |
| YoY Change | -84.67% | |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$259.6K | -$128.1K |
| YoY Change | 74.08% | -84.37% |
| Pretax Income | -$862.4K | -$758.1K |
| YoY Change | 19.26% | -43.47% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$862.4K | -$758.1K |
| YoY Change | 19.26% | -43.47% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$0.70 | -$0.62 |
| Diluted Earnings Per Share | -$0.70 | -$0.62 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 1.225M shares | 1.224M shares |
| Diluted Shares Outstanding | 1.238M shares | 1.230M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $32.80K | |
| YoY Change | -89.82% | |
| Cash & Equivalents | $53.64K | $32.84K |
| Short-Term Investments | ||
| Other Short-Term Assets | $42.73K | $51.59K |
| YoY Change | -22.53% | 28.46% |
| Inventory | $50.00K | $50.00K |
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $146.4K | $134.4K |
| YoY Change | 13.65% | -67.41% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $12.41K | $13.77K |
| YoY Change | -33.35% | -32.28% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $20.71K | $20.71K |
| YoY Change | 0.0% | 0.0% |
| Total Long-Term Assets | $173.8K | $188.9K |
| YoY Change | -25.42% | -23.83% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $146.4K | $134.4K |
| Total Long-Term Assets | $173.8K | $188.9K |
| Total Assets | $320.2K | $323.3K |
| YoY Change | -11.51% | -51.05% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $488.4K | $529.5K |
| YoY Change | 43.66% | 99.73% |
| Accrued Expenses | $1.141M | |
| YoY Change | 1085.72% | |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $2.477M | |
| YoY Change | 0.23% | |
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $3.900M | $4.235M |
| YoY Change | 20.14% | 49.46% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | |
| YoY Change | ||
| Other Long-Term Liabilities | $109.8K | |
| YoY Change | -36.55% | |
| Total Long-Term Liabilities | $92.69K | $109.8K |
| YoY Change | -41.37% | -36.54% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $3.900M | $4.235M |
| Total Long-Term Liabilities | $92.69K | $109.8K |
| Total Liabilities | $3.992M | $4.345M |
| YoY Change | 17.28% | 44.51% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$12.96M | -$12.10M |
| YoY Change | 39.98% | 41.74% |
| Common Stock | $126.00 | $122.00 |
| YoY Change | -97.15% | -97.15% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$3.672M | -$4.021M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $320.2K | $323.3K |
| YoY Change | -11.51% | -51.05% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$862.4K | -$758.1K |
| YoY Change | 19.26% | -43.47% |
| Depreciation, Depletion And Amortization | $1.364K | $1.523K |
| YoY Change | -20.47% | -11.2% |
| Cash From Operating Activities | -$235.6K | |
| YoY Change | -58.12% | |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | ||
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | ||
| YoY Change | ||
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | $256.8K | |
| YoY Change | -70.71% | |
| NET CHANGE | ||
| Cash From Operating Activities | -$235.6K | |
| Cash From Investing Activities | ||
| Cash From Financing Activities | $256.8K | |
| Net Change In Cash | $21.15K | |
| YoY Change | -93.26% | |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$235.6K | |
| Capital Expenditures | ||
| Free Cash Flow | ||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | us-gaap |
Gross Profit
GrossProfit
|
usd | |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
usd | |
| CY2023Q1 | us-gaap |
Gross Profit
GrossProfit
|
usd | |
| CY2024Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
usd | |
| CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
usd | |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
usd | |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
usd | |
| CY2024Q1 | SIGY |
Cancellation Of Common Stock Related Party In Value
CancellationOfCommonStockRelatedPartyInValue
|
usd | |
| CY2024Q1 | SIGY |
Post Split Rounding Of Shares In Value
PostSplitRoundingOfSharesInValue
|
usd | |
| CY2024Q1 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
usd | |
| CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
usd | |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
usd | |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
usd | |
| CY2023Q1 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
usd | |
| CY2023Q1 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
usd | |
| CY2024Q1 | us-gaap |
Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
|
usd | |
| CY2024Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
usd | |
| CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
usd | |
| CY2024Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
usd | |
| CY2023Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
usd | |
| CY2024Q1 | SIGY |
Beneficial Conversion Feature In Conjunction With Debt Issuance
BeneficialConversionFeatureInConjunctionWithDebtIssuance
|
usd | |
| CY2023Q1 | SIGY |
Cancellation Of Common Stock Related Party In Value Non Cash
CancellationOfCommonStockRelatedPartyInValueNonCash
|
usd | |
| CY2024Q1 | SIGY |
Conversion Of Debt For Common Stock
ConversionOfDebtForCommonStock
|
usd | |
| CY2024Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
usd | |
| CY2023Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
usd | |
| CY2024Q1 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
shares | |
| CY2023Q1 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
shares | |
| CY2024Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2024Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2024Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2024Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2024Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2024Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2024Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
1224827 | shares |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
32838 | usd |
| CY2024Q1 | us-gaap |
Inventory Net
InventoryNet
|
50000 | usd |
| CY2024Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
51590 | usd |
| CY2024Q1 | us-gaap |
Assets Current
AssetsCurrent
|
134428 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
13773 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
154383 | usd |
| CY2024Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
20711 | usd |
| CY2024Q1 | us-gaap |
Assets
Assets
|
323295 | usd |
| CY2024Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
529450 | usd |
| CY2024Q1 | us-gaap |
Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
|
1077662 | usd |
| CY2024Q1 | SIGY |
Advance From Shareholder
AdvanceFromShareholder
|
85000 | usd |
| CY2024Q1 | us-gaap |
Deferred Finance Costs Current Gross
DeferredFinanceCostsCurrentGross
|
307742 | usd |
| CY2024Q1 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
2476830 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
63237 | usd |
| CY2024Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
2569 | usd |
| CY2024Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4234748 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
109801 | usd |
| CY2024Q1 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
109801 | usd |
| CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
4344549 | usd |
| CY2024Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
32 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
32 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
32 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
32 | shares |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1000000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1224827 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1224827 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1288415 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1288415 | shares |
| CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
122 | usd |
| CY2024Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
8078224 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-12099600 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-4021254 | usd |
| CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
323295 | usd |
| CY2024Q1 | us-gaap |
Marketing Expense
MarketingExpense
|
338 | usd |
| CY2023Q1 | us-gaap |
Marketing Expense
MarketingExpense
|
184 | usd |
| CY2024Q1 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
37500 | usd |
| CY2023Q1 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
37500 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
232593 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
147843 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
359541 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
335731 | usd |
| CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
629972 | usd |
| CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
521258 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-629972 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-521258 | usd |
| CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-15806 | usd |
| CY2024Q1 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
1510 | usd |
| CY2023Q1 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
1139 | usd |
| CY2024Q1 | SIGY |
Interest Expense Debt Discount
InterestExpenseDebtDiscount
|
43207 | usd |
| CY2023Q1 | SIGY |
Interest Expense Debt Discount
InterestExpenseDebtDiscount
|
791708 | usd |
| CY2024Q1 | us-gaap |
Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
|
83399 | usd |
| CY2023Q1 | us-gaap |
Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
|
42737 | usd |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-128116 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-819778 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-758088 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1341036 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-758088 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1341036 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.62 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.62 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.39 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.39 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
1230354 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
1230354 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
961641 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
961641 | shares |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1903239 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
578016 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
|
303984 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
37500 | usd |
| CY2023Q1 | SIGY |
Stock Issued During Period Value Modification Of Warrants
StockIssuedDuringPeriodValueModificationOfWarrants
|
-15806 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
5456 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1341036 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2346037 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3412500 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
37500 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
111834 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-758088 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1341036 | usd |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
1523 | usd |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
1715 | usd |
| CY2023Q1 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
900 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
37500 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
37500 | usd |
| CY2024Q1 | SIGY |
Accretion Of Debt Discount
AccretionOfDebtDiscount
|
-43207 | usd |
| CY2023Q1 | SIGY |
Accretion Of Debt Discount
AccretionOfDebtDiscount
|
-791708 | usd |
| CY2024Q1 | SIGY |
Accretion Of Original Issuance Costs
AccretionOfOriginalIssuanceCosts
|
83399 | usd |
| CY2023Q1 | SIGY |
Accretion Of Original Issuance Costs
AccretionOfOriginalIssuanceCosts
|
42737 | usd |
| CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-15806 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-4783 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
28219 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
67804 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-62432 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
|
285908 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
|
11000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-1648 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-640 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-235612 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-562573 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Short Term Debt
ProceedsFromShortTermDebt
|
251760 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Short Term Debt
ProceedsFromShortTermDebt
|
882000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
25000 | usd |
| CY2024Q1 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
20000 | usd |
| CY2023Q1 | us-gaap |
Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
|
5456 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
256760 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
876544 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
21148 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
313971 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
11690 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
8356 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
32838 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
322327 | usd |
| CY2023Q1 | SIGY |
Beneficial Conversion Feature In Conjunction With Debt Issuance
BeneficialConversionFeatureInConjunctionWithDebtIssuance
|
303984 | usd |
| CY2024Q1 | SIGY |
Warrants Issued To Third Parties In Conjunction With Debt Issuance
WarrantsIssuedToThirdPartiesInConjunctionWithDebtIssuance
|
111834 | usd |
| CY2023Q1 | SIGY |
Warrants Issued To Third Parties In Conjunction With Debt Issuance
WarrantsIssuedToThirdPartiesInConjunctionWithDebtIssuance
|
578016 | usd |
| CY2024Q1 | us-gaap |
Notes Issued1
NotesIssued1
|
25176 | usd |
| CY2023Q1 | us-gaap |
Notes Issued1
NotesIssued1
|
88200 | usd |
| CY2024Q1 | SIGY |
Cancellation Of Common Stock Related Party In Value Non Cash
CancellationOfCommonStockRelatedPartyInValueNonCash
|
7 | usd |
| CY2024Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<p id="xdx_804_eus-gaap--BasisOfAccounting_zQj3LLrId0z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_827_zhSykDMXyESj">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and include all adjustments necessary for the fair presentation of the Company’s financial position and results of operations for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently operates in one business segment. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of businesses or separate business entities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20240331_zPvs8ARc6wDi" title="Accumulated deficit">12,099,600</span> at March 31, 2024, had a working capital deficit of $<span id="xdx_90A_ecustom--WorkingCapitalDeficit_iI_c20240331_zRHZQPu1VtW9" title="Working capital">4,100,320</span> at March 31, 2024, had net losses of $<span id="xdx_904_eus-gaap--NetIncomeLoss_iN_di_c20240101__20240331_zpMVcVczdEn4" title="Net loss">758,088</span> and $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_di_c20230101__20230331_zvyIS5enjFVd" title="Net loss">1,341,036</span> for the three months ended March 31, 2024 and 2023, respectively, and net cash used in operating activities of $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20240331_zSTVHQXLXKkf" title="Net cash provided by used in operating activities">235,612</span> and $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20230331_zC7e3NUPmHr8" title="Net cash provided by used in operating activities">562,573</span> for the three months ended March 31, 2024 and 2023, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Company is attempting to expand operations and increase revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a public offering or an asset sale transaction. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern for a year from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-12099600 | usd |
| CY2024Q1 | SIGY |
Working Capital Deficit
WorkingCapitalDeficit
|
4100320 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-758088 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1341036 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-235612 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-562573 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_840_eus-gaap--UseOfEstimates_zOERWyvoCC9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of these financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others: warrant valuation. The Company calculates the fair value of warrants using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value of the underlying common stock on the date of grant. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> | |
| CY2024Q1 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
250000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
15296 | usd |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
1523 | usd |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
1715 | usd |
| CY2024Q1 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
2784572 | usd |
| CY2023Q4 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
2507636 | usd |
| CY2024Q1 | SIGY |
Debt Instrument Original Discount
DebtInstrumentOriginalDiscount
|
-167612 | usd |
| CY2023Q4 | SIGY |
Debt Instrument Original Discount
DebtInstrumentOriginalDiscount
|
-225835 | usd |
| CY2024Q1 | SIGY |
Beneficial Conversion Feature
BeneficialConversionFeature
|
-12756 | usd |
| CY2023Q4 | SIGY |
Beneficial Conversion Feature
BeneficialConversionFeature
|
-22013 | usd |
| CY2024Q1 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
127374 | usd |
| CY2023Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
49489 | usd |
| CY2024Q1 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
2476830 | usd |
| CY2023Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
2210299 | usd |
| CY2024Q1 | us-gaap |
Advertising Expense
AdvertisingExpense
|
338 | usd |
| CY2023Q1 | us-gaap |
Advertising Expense
AdvertisingExpense
|
184 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
232593 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
147843 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
|
P5Y | |
| CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zrgUQPg146n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations, Risks, and Uncertainties</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Business Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantial business risks and uncertainties are inherent to an entity, including the potential risk of business failure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is headquartered and operates in the United States. To date, the Company has generated no revenues from operations. There can be no assurance that the Company will be able to raise additional capital and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. Currently, these contingencies include general economic conditions, price of components, competition, and governmental and political conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest rate risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets and liabilities do not have material interest rate risk.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Credit risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is exposed to credit risk from its cash in banks. The credit risk on cash in banks is limited because the counterparties are recognized financial institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Seasonality</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The business is not subject to substantial seasonal fluctuations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Major Suppliers</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sigyn Therapy is comprised of components that are supplied by various industry vendors. Additionally, the Company is reliant on third-party organizations to conduct clinical development studies that are necessary to advance Sigyn Therapy toward the marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should the relationship with an industry vendor or third-party clinical development organization be interrupted or discontinued, it is believed that alternate component suppliers and third-party clinical development organizations could be identified to support the continued advancement of Sigyn Therapy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
| CY2024Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
18425 | usd |
| CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
16902 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
13773 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
2507636 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
276936 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
2784572 | usd |
| CY2022Q4 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
2279316 | usd |
| CY2023 | SIGY |
Convertible Notes Payable Issued
ConvertibleNotesPayableIssued
|
1748520 | usd |
| CY2023 | SIGY |
Conversion Of Debt For Common Stock
ConversionOfDebtForCommonStock
|
-1520200 | usd |
| CY2023Q4 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
2507636 | usd |
| CY2023Q4 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
2507636 | usd |
| CY2024Q1 | SIGY |
Convertible Notes Payable Issued
ConvertibleNotesPayableIssued
|
276936 | usd |
| CY2024Q1 | SIGY |
Convertible Notes Payable Issued
ConvertibleNotesPayableIssued
|
276936 | usd |
| CY2024Q1 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
2784572 | usd |
| CY2024Q1 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
2784572 | usd |
| CY2022Q4 | SIGY |
Debt Instrument Note Discounts
DebtInstrumentNoteDiscounts
|
642660 | usd |
| CY2023 | SIGY |
Note Discounts Issued In Conjunction With Debt
NoteDiscountsIssuedInConjunctionWithDebt
|
1695859 | usd |
| CY2023 | SIGY |
Accretion Of Note Discounts
AccretionOfNoteDiscounts
|
2041182 | usd |
| CY2023Q4 | SIGY |
Debt Instrument Note Discounts
DebtInstrumentNoteDiscounts
|
297337 | usd |
| CY2023Q4 | SIGY |
Debt Instrument Note Discounts
DebtInstrumentNoteDiscounts
|
297337 | usd |
| CY2024Q1 | SIGY |
Note Discounts Issued In Conjunction With Debt
NoteDiscountsIssuedInConjunctionWithDebt
|
137011 | usd |
| CY2024Q1 | SIGY |
Note Discounts Issued In Conjunction With Debt
NoteDiscountsIssuedInConjunctionWithDebt
|
137011 | usd |
| CY2024Q1 | SIGY |
Accretion Of Note Discounts
AccretionOfNoteDiscounts
|
126606 | usd |
| CY2024Q1 | SIGY |
Accretion Of Note Discounts
AccretionOfNoteDiscounts
|
126606 | usd |
| CY2024Q1 | SIGY |
Debt Instrument Note Discounts
DebtInstrumentNoteDiscounts
|
307742 | usd |
| CY2024Q1 | SIGY |
Debt Instrument Note Discounts
DebtInstrumentNoteDiscounts
|
307742 | usd |
| CY2023Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
2210299 | usd |
| CY2024Q1 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
2476830 | usd |
| CY2024Q1 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
2476830 | usd |
| CY2023Q4 | us-gaap |
Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
|
0.81 | pure |
| CY2024Q1 | us-gaap |
Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
|
0.05 | pure |
| CY2024Q1 | SIGY |
Advance From Shareholder
AdvanceFromShareholder
|
85000 | usd |
| CY2023Q4 | SIGY |
Advance From Shareholder
AdvanceFromShareholder
|
80000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
25000 | usd |
| CY2023 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
19500 | usd |
| CY2024Q1 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
20000 | usd |
| CY2023 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
19500 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
191869 | usd |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
32 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
32 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
32 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
32 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1000000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1000000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1224827 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1288415 | shares |
| CY2023Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
559839 | shares |
| CY2023Q2 | us-gaap |
Debt Instrument Issued Principal
DebtInstrumentIssuedPrincipal
|
198000 | usd |
| CY2022Q4 | us-gaap |
Debt Instrument Issued Principal
DebtInstrumentIssuedPrincipal
|
145200 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
|
64100 | shares |
| CY2023 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
50000 | usd |
| CY2023 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
37500 | usd |
| CY2022 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
37500 | usd |
| CY2023Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
|
352965 | shares |
| CY2021Q2 | us-gaap |
Payments For Rent
PaymentsForRent
|
5955 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
17919 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
17919 | usd |
| CY2024Q1 | us-gaap |
Lease Cost
LeaseCost
|
17919 | usd |
| CY2023Q1 | us-gaap |
Lease Cost
LeaseCost
|
17919 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
18954 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
18402 | usd |
| CY2024Q1 | SIGY |
Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
|
18954 | usd |
| CY2023Q1 | SIGY |
Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
|
18402 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y5M1D | |
| CY2023Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y5M1D | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.10 | pure |
| CY2023Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.10 | pure |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
58188 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
79456 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
54225 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y5M1D | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.10 | pure |
| CY2024Q1 | SIGY |
Lease Liability Present Values
LeaseLiabilityPresentValues
|
173038 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
63237 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
109801 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
173038 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
18831 | usd |
| CY2024Q1 | us-gaap |
Lease Cost
LeaseCost
|
17919 | usd |
| CY2023Q1 | us-gaap |
Lease Cost
LeaseCost
|
17919 | usd |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
560896 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
773631 | shares |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-758088 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1341036 | usd |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
1230354 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
961641 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
1230354 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
961641 | shares |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.62 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.62 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.39 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.39 | |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |
